BackgroundTasmania is a large, relatively isolated island located south of mainland Australia with limited tertiary level paediatric oncology services.AimsTo benchmark regional outcomes for childhood acute lymphoblastic leukaemia (ALL) against published international standards.MethodsWe undertook a retrospective cohort study, analysing the clinical characteristics and health outcomes of all children diagnosed with and treated for ALL in Tasmania, Australia between 2006 and 2015.ResultsThirty‐five patients aged less than 18 years were diagnosed with ALL in the study's 10‐year period. Twenty‐eight cases were precursor B cell in origin, with 7 cases of T‐cell ALL. The great majority of children (30/35; 86%) received their entire first line treatment in Tasmania. Major treatment‐related toxicities, including allergic drug reactions, and episodes of acute pancreatitis, deep venous thrombosis and bacterial sepsis, were managed locally, with one death secondary to overwhelming infection and multiorgan failure. The overall and event‐free survival rates for childhood ALL were 30/35 (86%) and 28/35 (80%), respectively.ConclusionsThese results compare favourably with published results from large international cooperative group trials based in developed countries. Continued local treatment with appropriate support from a dedicated specialist paediatric oncology unit is therefore justified.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.